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Available online 29 December 2015Antigen speciﬁc immunotherapymediated via the sustained generation of regulatory T cells arguably represents
the ideal therapeutic approach to preventing beta cell destruction in type 1 diabetes. However, there is a need to
enhance the efﬁcacy of this approach to achieve disease modiﬁcation in man. Previous studies suggest that
prolonged expression of self-antigen in skin in a non-inﬂammatory context is beneﬁcial for tolerance induction.
We therefore sought to develop a dry-coated microneedle (MN) delivery system and combine it with topical
steroid to minimise local inﬂammation and promote prolonged antigen presentation in the skin. Here we
show that a combination of surface-modiﬁedMNs coatedwith appropriate solvent systems candeliver therapeu-
tically relevant quantities of peptide to mouse and human skin even with hydrophobic peptides. Compared to
conventional “wet” intradermal (ID) administration, “dry” peptide delivered viaMNs was retained for longer
in the skin andwhilst topical hydration of the skinwith vehicle or steroid accelerated loss of ID-delivered peptide
from the skin, MN delivery of peptide was unaffected. Furthermore, MN delivery resulted in enhanced presenta-
tion of antigen to T cells in skin draining lymph nodes (LNs) both 3 and 10 days after administration. Repeated
administration of islet antigen peptide via MN was effective at reducing antigen-speciﬁc T cell proliferation in
the pancreatic LN, although topical steroid therapy did not enhance this. Taken together, these data show
auto-antigenic peptide delivery into skin using coatedMNs results in prolonged retention and enhanced antigen
presentation compared to conventional ID delivery and this approach may have potential in individuals identi-
ﬁed as being at a high risk of developing type 1 diabetes and other autoimmune diseases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Type 1 diabetes (T1D) is an autoimmune disease characterised by T-
cell mediated destruction of insulin-producing beta cells in the pancre-
atic islets. Antigen speciﬁc immunotherapy (ASI) is the preferred ap-
proach for immunotherapy of T1D as it offers the possibility of halting
beta cell destruction without systemic immunosuppression. We have
previously reported the results of a phase 1A clinical trial in patients
with long standing T1D, in which a proinsulin peptide, C19-A3, was ad-
ministered via intradermal (ID) injection. This approach was shown to
be safe, and in a subset of patients, increased the number of C19-A3 re-
active, IL-10-producing T cells in the peripheral blood [1]. Others have
also demonstrated the safety of ASI but although some protocols have
showed promise they are not yet sufﬁciently powerful to induce toler-
ance [2]. Previous research in the non-obese diabetic (NOD) mouse. This is an open access article undermodel of diabetes has shown that tolerance to pancreatic self-antigens
can be induced using peptide immunotherapy and that this effect can
be enhanced through the systemic administration of glucocorticoids
(GC) [3]. However, the long-term oral administration of GC is undesir-
able as it is associatedwith notable adverse effects and therefore topical
GC application offers a more clinically desirable alternative.
We have previously demonstrated that even an ID injection of PBS
can provoke a proinﬂammatory response, most likely caused by the
physical trauma of the locally injected ﬂuid bolus [4–6]. This is undesir-
able for the induction of tolerance. Solid microneedle (MN) delivery, in
which the therapeutic antigen is “dry coated’ onto the outer surface of
multiple microscopic needles, potentially represents an alternative ap-
proach involving less trauma, no skin layer distension, improved anti-
gen delivery to the dermis and epidermis and prolonged retention of
the antigen in the skin. MN drug delivery devices generate less pain
and irritation than conventional hypodermic needles [7–9]. Minimal
skin damage also reduces microbial penetration through MN treated
skin compared to conventional needles, thus reducing the risk of infec-
tion [10,11].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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on the surface of the needle and delivery is achieved by drug diffusion
from the needles and into the skin during skin insertion [12]. Such
MNs have been used widely in vaccination studies to deliver inﬂamma-
tory particles, for example inactivated inﬂuenza virus, virus-like particle
vaccines and DNA vaccines, showing highly effective induction of local
and systemic [13–16] and protective memory [17,18] immune
responses. MN delivery of vaccines is able to induce stronger immune
responses, compared to intramuscular or ID injection, due to improved
targeting of the antigen to skin-resident dendritic cells (DCs) [19,20]. Re-
cently, solid-coatedMNs have been proposed as amore effectivemethod
of delivery to facilitate allergen immunotherapy, with authors reporting
an elevated Th1 response, against the model antigen ovalbumin, com-
pared to SC injection [21]. However, to date MN systems have not been
used for the ID delivery of peptides to induce tolerance against autoim-
mune disease.
As well as being vaccination targets, the DCs of the epidermis and
upper dermis clearly have tolerogenic potential in the resting state
[22]. There may be an opportunity to promote a tolerogenic response
in the DCs by optimising the environment using topically applied
tolerogenic agents. For example, local treatment using GC can inﬂuence
the maturation of DCs and thus promote the induction of regulatory T
cells [23–26]. Short-term topical GC is well tolerated [6] however we
recognise that long-term treatment may reduce Langerhans cell num-
bers in the epidermis [27–30].
In this project, we therefore hypothesise that delivery of auto-
antigen to the upper layers of the skin using a minimally invasive MN
delivery method, and a non-stimulatory coating formulation, might
provide a less inﬂammatory andmore efﬁcientmeans of loading resting
DCs than standard ID injection for tolerance induction. This study aims
to exemplify, for the ﬁrst time, the development of such a delivery sys-
tem towards the future goal of preserving endogenous insulin produc-
tion in type 1 diabetes. The painless nature of the delivery method
and its suitability for self-administrationmake this a particularly attrac-
tive proposition for this patient group. Furthermore, the study also ex-
plores the potential of topical application of GC as a means to enhance
any peripheral tolerance induced using MNs coated with auto-antigen.
2. Materials and methods
2.1. Reagents
All antibodies were purchased from BioLegend, eBioscience and
BD. ELISAs were from R&D. Peptides were from GLS China
manufactured to N95% purity with sequences as follows: BDC2.5
mimotope — YVRPLWVRME [31]; WE14 — WSRMDQLAKELTAE
[32]; Epstein–Barr virus peptide (EBVP1) (lytic protein BMLF-1)
(280–288)-GLCTLVAML [33], and Insulin B9-23-SHLVEALYLVCGERG.
2.2. Animal models
The BDC2.5 TCR transgenic NOD mouse expresses diabetogenic
CD4+ T cells that recognise the WE14 peptide from chromogranin A
after it has been post-translationally modiﬁed [32]. Mice were main-
tained in individually-ventilated ﬁlter cages in scantainers in a speciﬁc
pathogen free facility on a 12 h light/dark cycle. All procedures were
performed in accordance with protocols approved by the UK Home
Ofﬁce.
2.3. Intradermal injection of peptide
Mice were anaesthetised using isoﬂurane and the site of injection
was shaved using electric clippers prior to injection. Peptide was pre-
pared in sterile PBS at a dose derived from the MN delivery efﬁciency
studies and injected in a volume of 50 μl using a 29G insulin needle
for mice and a 26G needle for human skin.2.4. Manufacture of MNs
MNs were wire cut from stainless steel sheets using wire electrical
dischargemachining (wire-EDM) performed at the Cardiff School of En-
gineering. TheMNswere subsequently electro-polished using amethod
adapted from that described previously [12,34]. An electrolyte bath was
heated to 70 °C. The cathode was connected to a copper plate and the
anode was connected to a MN array. A current of 1.8 mA/mm2 was
applied for each MN array for 15min using mechanical agitation of the
MNs to remove air bubbles. After electro-polishing, the MNs were
washed for 30 s in deionised (DI) water followed by 25% v/v nitric
acid solution and then rinsed in hot running tap water before a ﬁnal
rinse in DI water. MNs were then air-dried, wrapped in lens tissue and
kept in an airtight container.
A bespoke MN holder and application device was manufactured
from biocompatible acrylate polymer (e-Shell 200; EnvisionTEC) at
the Cardiff School of Engineering using additive manufacturing. The
applicator was designed to facilitate simultaneous insertion of three
planar rows of MNs.2.5. Imaging of MNs
MNs were inspected using a stereo microscope. The surface mor-
phology of MNs was imaged using a scanning electron microscope
(SEM). All pictures were post-processed using ImageJ software.2.6. Preparation of peptide coating formulation
BDC2.5mimotope (with orwithout 5-carboxytetramethylrhodamine
(5-TAMRA)) was prepared in 2.5 mg/ml polyvinyl alcohol (MW2000)
(PVA 2000), 20% v/v 2-methyl-2-butanol and 11% v/v acetic acid in
water. WE14 (with or without 5-TAMRA) was prepared in 2.5 mg/ml
PVA 2000 and 15% v/v acetic acid. EBVP1 peptide was dissolved in
2.9 mg/ml PVA 2000, 59% v/v glacial acetic acid and 29% v/v 2-methyl-
2-butanol. B9-23 was prepared in 1.25 mg/ml PVA 2000, 31.25% v/v 2-
methyl-2-butanol and 12.5% v/v acetic acid in water.
To coatMNs, 0.4 μl of BDC2.5mimotope andWE14, or 0.8 μl of B9-23
and EBVP1 formulation (containing 10 μg peptide)was taken up using a
pipette and 10 μl ultra-long tip. The droplet in the tipwas repeatedly ap-
plied to three rows of ten MNs resulting in a nominal coating of 10 μg
peptide spread across 30 individual MNs.2.7. Administration of peptide to mice using MNs
To apply MNs in vivo, theMN arrays weremounted in the applicator
device, manually inserted into the shaved skin of an anaesthetised
mouse and held in place for 10 min. The delivery efﬁciency of 5-
TAMRA conjugated peptides was calculated by measuring the mass of
peptide remaining on the MN device following insertion. To determine
the remaining peptide the MNs were washed in 10% v/v acetic acid and
the resulting solution of peptidewas quantiﬁed using UV–vis spectrom-
etry at the maximum absorption wavelength of 559 nm (as identiﬁed
from a wavelength scan between 200 nm and 800 nm; Nanovue®).
The delivery efﬁciency of peptides was then calculated using the equa-
tion below:
%delivered ¼ mass before delivery−mass post deliveryð Þ= mass before deliveryð Þ x 100:
The same UV–vis quantiﬁcation method was also used in delivery
efﬁciency experiments performed in excised human skin. Fluores-
cence quantiﬁcation was not employed due to the inherent auto-
ﬂuorescence that is associated with mouse and human skin.
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In steroid pre-treatment studies a 0.1 ml volume of cream was ap-
plied to the shaved back of the neck and gently massaged into the
skin. To study the systemic effect of betamethasone, DiproSone®
0.05% w/w Cream (0.05% w/w betamethasone dipropionate; Schering
Plough) was used either in its original form or following a 1/50
(0.001% w/w) dilution in Diprobase Cream (geometric dilution on a
ceramic tile).
2.9. Flow cytometry
Flow cytometric analysis was performed on a BD Canto II with data
analysed by FlowJo. Cells were gated on singlet cells, and dead cells
were excluded using a ﬁxable viability dye (eBioscience).
2.10. In vivo imaging of peptide distribution in murine skin
NODmice (5–7weeks old) were shaved in the neck area under gen-
eral anaesthetic. Mice were imaged before and after peptide delivery
(via ID injection andMNarray) using a Kodak Fx Pro in vivo imaging sys-
tem. Imageswere analysed usingCarestreamMI software. For eachﬂuo-
rescent image, the same area of the region of interest (ROI) was applied
to all the data. Net intensity for the ROI was calculated by subtracting
net intensity of the skin prior to treatment from the values obtained
from the treated area. The normalised relative intensity (NRI) was cal-
culated using the following equation:
NRI %maxð Þ ¼ Net intensity at each time point=Maximum net intensityð Þ x 100:
Mice were imaged before treatment and then 1, 4 and 24 h post
treatment. Between each time point, the mouse cage was maintained
at 26 ± 1 °C.
2.11. CFSE-labelled cell transfer
CD4+ T cells were separated from splenocytes using a MACS CD4 II
isolation kit from Miltenyi Biotec. Cells were labelled with 20 μM
CFDA (Invitrogen) in 10% FCS RPMI at room temperature for 5 min at
a concentration of 107/ml. Cells were then washed twice in RPMI con-
taining 10% foetal calf serum (FCS) and rested for 15 min in the same
media. Cells were subsequently washed in saline, re-suspended at
4 × 106 cells in 200 μl sterile saline and injected into a tail vein using a
27G needle.Fig. 1. Design of MNs suitable for both human and mouse studies. A. Individual needle
dimensions (μm): 500 (L) × 200 (W) × 100 (D); B. MN array design. Each MN array
contains 10 needles (A) spaced 1 mm apart. A channel was designed in the centre of
each MN array so that MNs can be held together using a bespoke MN holder (F & G); C.
A single stainless steel MN array (left) shown with a 29G insulin injection needle for
scale (right); D. Coating technique; Each needle was manually coated with peptide
using a ﬁne pipette tip, ﬁlled with 10 μg peptide (pink); E. Scanning electron
microscopy (SEM) image of a MN tip before and after electropolishing; F. The elements
contained in each MN set; the 3 MN arrays are held in place between the end plates and
are separated by spacers; G. Sequential assembly of a MN set. MN arrays are located on
the male end piece as shown (1, 3 and 5), each followed by a spacer (2 and 4). The
female end piece completes the assembly (6), which is then carefully tightened and
secured with a screw (7); H. MNs with and without electropolishing were coated with
10 μg BDC2.5-5TAMRA mimotope peptide and applied to mouse skin for 10 min. The
remaining peptide was dissolved off the MN and analysed by UV–vis
spectrophotometric analysis to calculate the % delivered to skin (***p b 0.001 unpaired t
test n = 3, Mean ± SD); I. Polished MNs were coated with 10 μg of either BDC2.5-
5TAMRA or WE14-5TAMRA and the amount delivered to the skin was quantiﬁed as
above (***p b 0.001 unpaired t test n = 3–11, Mean ± SD).
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Skin samples were obtained from female patients aged 19–82 years,
following mastectomy or breast reduction after informed consent. Skin
without obvious pathological ﬁndings, that was surplus to diagnostic
histopathology requirements, was used in the experiments. The study
received full ethical approval from South East Wales Research Ethics
Committee, UK.
Subcutaneous adipose tissue was removed by blunt dissection to
yield full-thickness skin. EBVP1 was coated on MNs, which were then
applied to ex vivo human skin and kept in situ for 15 min. Skin samples
were also treated withMNs coated with vehicle only (negative control)
or by ID injection of 2 μg (equivalent toMN delivery amount) of peptide
in 50 μl of PBS using a 26G hypodermic needle.
Treated skin was isolated as previously described [6] using a dispos-
able 0.8 cm biopsy punch and punches were then cultured at the air-
liquid interface using cell culture inserts andDMEMmedia supplemented
with 50 IU/ml penicillin and 50 μg/ml streptomycin at 37 °C in 5% (v/v)
CO2/95% (v/v) air for 16–18 h [35]. After incubation, a single cell suspen-
sionwas obtained and co-culturedwithHLA-A*0201 (HLA-A2) restricted
EBVP speciﬁc cloned T cells for 12 h. Supernatants were harvested for
Macrophage Inﬂammatory Protein 1β (MIP-1β) measurements by
ELISA (human CCLR/MIP-1β, DuoSet® Development System, R&D Sys-
tems, Abingdon, UK).
2.13. Statistical analysis
Data are expressed as mean ± SD. Statistical signiﬁcance of differ-
ences was determined using unpaired t tests or one-way ANOVA,
followed by appropriate post hoc tests. P-values are expressed in the ﬁg-
ure legends. Statistical analysis was performed using GraphPad Prism
software.
3. Results
3.1. Coated MNs for the delivery of peptides into murine skin
Solid MNs with dimensions of 500 μm (L) × 200 μm (W) (Fig. 1A)
were prepared by wire electro-discharge machining (EDM) of 100 μm
thick stainless steel sheets. The MNs were composed of 10 in-plane
needles, each 1 mm apart (Fig. 1B). In this study MN delivery was com-
pared to standard ID injection using a 29G insulin needle (Fig. 1C). MNs
were coated with various peptides using a simple yet reproducible pi-
pette tip method (Fig. 1D) [36]. Needles were left unpolished or
deburred and sharpened by electropolishing prior to coating (Fig. 1E).
The polishing process reduced the length of the MN by approximately
50 μm, to give a length of approximately 450 μm. Electropolishing the
MNs prior to coating increased the efﬁciency of delivery of peptides
into murine skin, with 60% of the WE14-TAMRA peptide delivered to
skin when coated onto 30 electropolished needles versus 2% delivery
from unpolished MNs (Fig. 1H). Therefore all further experimentsFig. 2.MN delivery improves skin retention of peptide vs. ID injection. Mice were injected
with 2 μg BDC2.5-5TAMRA unless otherwise stated, using conventional ID or coated-MN
injection. A. The total ﬂuorescence was measured before and immediately after injection
and again 1, 4 and 24 h post injection using a Kodak in vivo imaging system (BDC2.5-
5TAMRA). Images presented are from a single experiment representative of at least 3
independent experiments; B. The percentage of the maximum ﬂuorescence at each
timepoint was calculated in for BDC2.5-5TAMRA delivered by ID or MN (n = 6); C. The
percentage of the maximum ﬂuorescence at each timepoint was calculated for each
mouse for WE14-5TAMRA delivered by ID or MN (n = 3); D. Comparison of ID injection
of BDC2.5-5TAMRA and WE14-5TAMRA; E. Comparison of MN injection of BDC2.5-
5TAMRA and WE14-5TAMRA; F. Mice were pretreated with GC cream for 2 days before
ID injection of BDC2.5-5TAMRA; G. Mice were pretreated with GC cream for 2 days
before MN injection of BDC2.5-5TAMRA (n = 7). H. The AUC of maximum ﬂuorescence
vs. time was calculated for each mouseover the 24 h period (*p b 0.05, ***p b 0.001,
****p b 0.0001 One way ANOVA with Tukey's post test, Mean ± SD). AUC = area under
curve.
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biocompatible polymer applicator device (Fig. 1F and G) to enable 30
MNs to be administered in a single application. We then compared de-
livery between peptides of different composition. When 10 μg of either
BDC2.5 mimotope peptide conjugated to the ﬂuorescent TAMRA tag
(BDC2.5-5TAMRA) or WE14-5TAMRA (WE14 is more hydrophilic than
BDC2.5 mimotope) was coated onto 30 MNs we found that 19.5% vs.
58.2% of coated BDC2.5 mimotope or WE14 peptide, respectively, was
delivered to skin (Fig. 1I). Hence in further experiments, whilst 10 μg
of peptide was coated onto all solid MN, the dose of peptide delivered
into skin was considered to be 2 μg for BDC2.5 mimotope and 6 μg of
WE14, and equivalent doses were therefore also delivered by ID injec-
tion for the ID controls.
3.2. Comparison of pharmacokinetics of ID and MN delivery of peptide
Fluorescently-tagged peptides and the Kodak intravital imaging sys-
temwere used tomonitor peptide retention in the skin following deliv-
ery (Fig. 2A). In order to standardise experiments and peptides, the
ﬂuorescence was calculated as a percentage of maximum ﬂuorescence
for each mouse. Fluorescence of BDC2.5-5TAMRA injected ID fell by
25% at 1 h and declined to near baseline by 4 h. However, MN-injected
peptide intensity increased over the ﬁrst hour (the TAMRA tag only
ﬂuoresces in solution) and then declined slowly, with ~45% of themax-
imum ﬂuorescence remaining at the 4 h time-point, before decreasing
to comparable levels to ID injection at 24 h (Fig. 2B). The signal from
the peptide with higher solubility, WE14-5TAMRA, followed the same
general trend (Fig. 2C) however side by side comparisons (Fig. 2D and
E) of the clearance kinetics of the two peptides reveal some subtle dif-
ferences. For example, when administered by ID injection, the ﬂuores-
cent signal of WE 14-5TAMRA dropped sharply within 1 h compared
with BDC2.5-TAMRA. At the 4 h timepoint, WE14-5TAMRA was almost
entirely eliminated from the skin, whilst BDC2.5-TAMRAwas still trace-
able (Fig. 2D). Using MN delivery, both WE14-5TAMRA and BDC2.5-
TAMRA showed similar skin clearance kinetics within the ﬁrst hr. How-
ever, WE14-5TAMRA was cleared more quickly from the skin from 1 h
onwards (Fig. 2E).
As ID application of peptides for ASI offers the opportunity of modu-
lating local DCs to improve tolerance induction without systemic side
effects, we also pre-treated the skin with GC cream for two days prior
to peptide application. The clearance of BDC2.5-TAMRA was initially,
i.e. within the ﬁrst hr, twice as rapid following ID administration in
mice pretreated with GC cream (40% of maximum intensity compared
with 80% in non-GC treated mice) (Fig. 2F). However, when MNs were
used to administer BDC2.5-TAMRA there was no statistically signiﬁcant
difference in peptide signal in the skin at 1, 4 and 24 h in steroid pre-
treated and non-treated mice, although the initial signal (immediately
after injection) was slightly higher in GC-treated mice (60% compared
with 40%) presumably due to enhanced solubility of the peptide in the
more hydrated skin (Fig. 2G). To investigate whether the altered effect
on pharmacokinetics after ID administration to GC-treated skin could
have been due to a deleterious effect of GC on skin integrity [37], we re-
duced the time that GC creamwas applied to as little as 1 h before pep-
tide injection and found that this or a placebo vehicle cream also caused
a reduction in peptide retention (Supplementary Fig. 1).Fig. 3. Proliferation of transferred BDC2.5 T cells following topical peptide administration.
A. Female NODmice were given 2 μg BDC2.5 mimotope peptide by ID injection or coated
MNs and 4 × 106 CFSE-labelled BDC2.5 CD4+ T cells were transferred. CFSE dilution was
assessed after 72 h. Representative ﬂow cytometry plots from pancreatic lymph node
(PLN), axillary LN (ALN), spleen (SP), cervical LN (CLN), inguinal LN (ILN) and paraaortic
LN (ParaLN) from one experiment representative of two independent experiments are
shown. B. Graph summarizing proliferation in axillary LN (ALN) at 3 days post
treatment (*p b 0.05 **p b 0.01 one way ANOVA followed by Bonferroni post test); C.
Graph summarizing proliferation in pancreatic LN (PLN) at 3 days; D. Proliferation in
ALN at 10 days (**p b 0.01 ***p b 0.001 one way ANOVA followed by Bonferroni post
test); E. Proliferation in PLN at 10 days. All data are presented as Mean ± SD.
Fig. 4. Peptide delivered to human skin explants usingMNs is presented to T cell clones. A.
EBVP1 peptide, Insulin B9-23 and WE14 were coated onto arrays of MNs and the MNs
were applied to human skin explants. The remaining peptide was dissolved off the MN
and analysed by UV–vis spectrophotometric analysis to calculate the % delivered to skin
(****p b 0.0001, One way ANOVA followed by Bonferroni post-test); B. MNs were coated
with 10 μg WE14 and applied to human skin explant or mouse skin. The percentage
delivered was calculated by UV–vis spectrophotometric analysis (**p b 0.01, unpaired t
test). C. EBVP1 peptide (2 μg) was delivered to human skin explants from HLA-A2
negative or positive donors by standard 26G needle (ID) or dry coated MNs. The
epithelium was mechanically and enzymatically digested to a single cell suspension and
used to present peptide to the T cell clone. MIP-1β produced by the T cells was
measured and expressed as a ratio of peptide treated/untreated controls (*p b 0.05, One
way ANOVA followed by Bonferroni post-test). All data are presented as Mean ± SD.
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total AUC of %maximumﬂuorescence vs. time for the 24 h experimental
period (Fig. 2H). AUC is inversely correlated with the clearance rate,
therefore the higher the AUC the lower the clearance rate. The AUC for
BDC2.5-TAMRA peptide administered via coated MNs (832.6 ± 115.1)
was signiﬁcantly higher than for peptide administered via ID injection
(336.7 ± 92.99) conﬁrming a slower skin clearance rate for MN deliv-
ered peptide. There was also a signiﬁcant increase in AUC when
WE14-TAMRA was given by MN (595.5 ± 111.6) rather than ID injec-
tion (162±45.54). Looking at the above data therefore, peptide solubil-
ity was conﬁrmed to play a role in clearance with MN delivery of
BDC2.5-5TAMRA showing a signiﬁcantly higher AUC than the relatively
more soluble WE14-5TAMRA. Despite the aforementioned observation
of an initial increase in clearance of BDC2.5 peptide administered via
ID injection following skin pre-treatment with GC cream the AUC over
24 h was not signiﬁcantly affected (300.2 ± 177.2 for steroid pre-
treated skin vs. 336.7 ± 92.99 for non-treated skin).
3.3. Antigen presentation in draining LN following ID and MN peptide
administration
To determine if the apparently longer retention of peptide in skin
followingMNdelivery results in greater peptide delivery to the draining
LN, we explored the potential of MN versus ID peptide to stimulate T
cells. Following transfer of islet-speciﬁc BDC2.5 T cells into an untreated
NODmouse, the T cells proliferated at the site where they encountered
their cognate antigen i.e. in the pancreatic LN (PLN) (~50% of cells pro-
liferated), aswell as undergoing a low level of proliferation in the spleen
and other LNs (b5%). This was observable at 72 h post transfer (Fig. 3A).
The high afﬁnity BDC2.5 mimotope peptide was administered into the
skin of the back of the neck (at the same time as the BDC2.5 T cells
were transferred). After 72 h, the BDC2.5 T cells were observed to pro-
liferate in the skin-draining (axillary) LN (ALN) as well as the PLN, but
not in non-draining LNs (cervical (CLN) or inguinal (ILN)) (Fig. 3A).
MN administration of peptide resulted in a higher and more consistent
level of proliferation in the skin-draining LN compared to ID injection
(78% ± 9 SEM MN vs. 39.6% ±23.6 ID) (Fig. 3B). ID or MN-
administered peptide had no effect on proliferation in the PLN at this
early time point (Fig. 3C). To test for prolonged antigen retention in
skin and delivery to draining LN, we repeated the experiment with
cells transferred into mice 7 days after a single treatment with peptide,
and examined proliferation at day 10 in the ALN. The response to MN-
delivered peptide continued to be greater than to ID peptide, with less
variability (MN 67.25 ± 2.2 SEM vs. ID 27.58 ± 12.8) (Fig. 3D). Again,
no changes in the level of proliferation in the PLN were observed
(Fig. 3E).
3.4. Delivery of peptide into ex vivo human skin
Human skin is architecturally very different frommouse skin, with a
10-fold thicker epidermis, a dermis that is millimetres thick and more
subcutaneous tissue. We therefore sought to determine the ability of
MNs to effectively deliver peptide to human skin.MNs of 500 μmlength,
coatedwith 10 μg of EBVP1,were inserted into human skin explants and
kept in place for 15 min. Spectrophotometric analysis of the EBVP5-
TAMRA, which, like BDC2.5 mimotope, is another poorly-soluble pep-
tide, remaining on the MNs indicated that 17.0 ± 1.4% of the coated
peptidewas deposited in the skin (Fig. 4A).We also examined the deliv-
ery efﬁciency of Insulin B9-23 and WE14 peptides to human skin ex-
plants which were found to be 46.5% and 81.4% respectively (Fig. 4A).
The delivery efﬁciency ofWE14was compared between human skin ex-
plant and mouse skin (Fig. 4B). Signiﬁcantly more peptide was deliv-
ered to human skin (81.4 ± 2.6% vs. 58.2 ± 4.2%).
To study delivery of antigen to local DCs in human skin, the EBVP1
peptide was delivered to human skin explants that were then main-
tained in organ culture. After 16–18 h, the skin epithelial cells (ECs)were harvested to make a single cell suspension and incubated with
an EBVP1-speciﬁc T cell clone. The response measured by MIP-1β pro-
duction (expressed as a ratio of peptide treated/non treated cultures)
showed signiﬁcant increases in MIP-1β production when peptide was
delivered by MNs (Fig. 4C) in HLA-A2 positive donors versus HLA-A2
negative donors. MIP-1β production was not signiﬁcantly increased
when peptide was administered by ID injection. Presentation was
shown to be speciﬁc, as no response was seen with ECs from donors
that did not carry the MHC-restriction element (HLA-A2) for this pep-
tide (Fig. 4C). It is however not possible to examine the time course of
peptide retention using such ex vivo systems.
3.5. Downregulation of the in vivo response to endogenous pancreatic anti-
gen following administration of peptide by MN versus ID injection
To attempt to induce immune tolerance by auto-antigenic peptide
administration, we administered two doses of peptide, three weeks
apart, by either MN or ID injection, to female NOD mice. CFSE-labelled
BDC2.5 T cells were then adoptively transferred and we assessed prolif-
eration in response to endogenous antigen presentation in the PLN
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islet inﬁltrating T cells, did not induce tolerance in this protocol
(Fig. 5B). Although low-dose administration of 6 μg of the low-afﬁnity
WE14 peptide did not induce a signiﬁcant decrease in proliferation of
the transferred T cells in the PLNwhen administered ID, therewas a sig-
niﬁcant decrease in proliferation when this dose ofWE14 was adminis-
tered using MNs. A much higher dose of 50 μg of WE14was required to
achieve a signiﬁcant response reduction using the ID route (Control
50.4% ± 1.3, ID 6 μg 42.7 ± 2.8 MN 6 μg 36.5 ± 3.4, ID 50 μg 28.5 ±
3.3) (Fig. 5C).
3.6. The effect of topical GC on tolerance induction
We sought to further optimise tolerance induction by pre-treatment
with topical glucocorticoid (GC) cream. GC cream did not however im-
prove tolerance with BDC2.5 mimotope or WE14 peptides, despite ef-
forts to titrate the dose to limit systemic side effects (Fig. 6).
4. Discussion
Wehave developed a protocol that uses non-inﬂammatory formula-
tions to coat soluble and insoluble peptides onto electropolished steelFig. 6. Tolerisation followed by transfer of CFSE labelled BDC2.5 T cells: A.Micewere given
2 doses of peptide 3 weeks apart by MN or ID injection. Before each dose of peptide mice
were pre-treated with GC (B) or GC diluted 1/50 in vehicle cream (C). CFSE-labelled
BDC2.5 T cells were transferred 7 days after the last injection and mice were culled after
72 h and the presence of proliferated BDC2.5 T cells was assessed in LNs as shown in the
schematic. B. Graph illustrating proliferation of BDC2.5 T cells after 2 μg BDC2.5
mimotope peptide with or without GC cream. C. Graph illustrating proliferation of
BDC2.5 T cells after 6 μg WE14 peptide with or without 1/50 GC cream. All data
presented as Mean ± SD.
Fig. 5. Tolerisation followed by transfer of CFSE-labelled BDC2.5 T cells: A.Micewere given
2 doses of BDC2.5mimotope peptide (B) orWE14 peptide (C), 3 weeks apart byMN or ID
injection. CFSE-labelled BDC2.5 T cells were transferred 7 days after the last injection and
mice were examined after 72 h and the presence of proliferated BDC2.5 T cells was
assessed in LNs and spleen. B. After administration of 2 μg BDC2.5 mimotope peptide: %
CFSE+ cells proliferated in PLN. C. After administration of WE14 peptide: % CFSE+ cells
proliferated in PLN (**p b 0.01 one way ANOVA followed by Dunnett's post test). All
data are presented as Mean ± SD.MNs that can deliver signiﬁcant quantities of peptides into mouse and
human skin. Here we show that MN-delivered peptide is retained in
the skin for longer and results in greater delivery to the immune system
than ﬂuid-phase peptide administered by standard ID hollow needle in-
jection. When we administered low afﬁnity peptide as two separate in-
jections over a 21 day period, the peptide coated onto MNs was more
efﬁcient at reducing the response to self-antigen in the pancreas in the
NOD mouse model of diabetes than the same dose of peptide in ﬂuid
phase (ID), suggesting that this approach may be beneﬁcial for toler-
ance induction. Peptide delivered in solid phase, using coated MNs,
was also better retained in the skin than ID injection of ﬂuid phase pep-
tide following pre-treatment with topical GC cream. However, in the
protocols used, topical GC therapy abrogated rather than enhanced tol-
erance induction for bothmethods of delivery and thereforemay not be
required in the clinical protocol.
The delivery of peptide into skin using coatedMNs is predominantly
determined by the detachment of the peptide from MN surface and
peptide dissolution in skin. The efﬁciency of the ﬁrst process is related
to MN surface morphology. The reduction of MN surface roughness,
by electropolishing, minimised the retention of the coated material to
the needle surface, which enabled efﬁcient delivery of MN load upon
skin insertion. The efﬁciency of the second process is related to factors
such as peptide solubility, formulation excipients, the thickness of the
coating and the skin condition [34]. The combined effect of these two
processes determines the ﬁnal delivery dose of coated peptide. The
185X. Zhao et al. / Journal of Controlled Release 223 (2016) 178–187restricted water content of the skin limits the amount of peptide that
can be dissolved during the insertion period. This limitation is particu-
larly problematic when coating peptides of increased hydrophobicity,
such as the BDC2.5 mimotope peptide; nevertheless we were able to
consistently and reproducibly deliver the coated peptide into the skin.
MN delivery of the WE14 peptide is more efﬁcient than the BDC2.5
mimotope, in line with its increased solubility. The BDC2.5 mimotope
peptide was also retained for longer in the skin than WE14, which
again reﬂects their respective solubilities.
It is well known that there are a variety of tolerogenic APCs in the
skin, which take up antigen in situ and then migrate to the draining
LN to exert tolerogenic effects [38,39]. However, ID-delivered peptides
can alsomove in a ﬂuid phase to the draining LN to be presented by res-
ident DCs [40,41]. Skin DCs are able to take up peptide between 40 and
360 min post treatment [42] and appear in the draining LNs just 24 h
after exposure to antigen [43]. Our data tracking ﬂuorescently-labelled
peptide suggests that most peptide is cleared from the skin in mice
within 4 h post ID injection, which limits the time available for antigen
uptake by APCs in the skin.
We demonstrated that MN application led to prolonged retention of
peptide in the skin compared to ID injection, which would be expected
to facilitate uptake by APCs in the skin and hence to favour tolerance in-
duction. Prolonged exposure to antigen is beneﬁcial to tolerance induc-
tion [44]; therefore the more sustained presentation in the draining LN
observed when peptide was administered byMN is also likely to be rel-
evant to tolerance induction. Others have shown that dose escalation
protocols can induce tolerance [45], and this relies upon accurate deliv-
ery of known doses. We hypothesise that the highly reproducible cellu-
lar response to MN-delivered peptide would make MNs delivery ideal
for these procedures. Importantly, this study has also demonstrated
that peptide coated onto solid MNs using our non-inﬂammatory sol-
vents, can be delivered into human skin and functionally presented by
dermal APCs to T cells.
MNs have been shown to reduce trauma at the injection site [46].
This is essential for a protocol aimed at inducing tolerance, as any in-
ﬂammation at the injection site may lead to activation of Langerhans
cells and dermal DCs and could result in a sensitisation response to
the peptide [47]. Solid MNs have previously been used to deliver pep-
tides and vaccines; however these are often coated with immunogenic
coating formulations. In order to reduce immunogenicity we therefore
coated our MNs by dissolving the peptide in a solution of PVA. PVA
2000 is known to be a useful excipient for in vivo and in vitromedical ap-
plications due to its documented stability, biocompatibility and low tox-
icity [48]. ID injection delivers the peptide to the lower dermis, whereas
MNs administer peptide more superﬁcially and are able to target the
epidermis and papillary dermis (as result of the dip-coating procedure
used to apply peptide). Thismay be advantageous for tolerogenic proto-
cols as others have shown that Langerhans cells (which reside in the
epidermis) in particular can be excellent mediators of tolerance [39].
Using the reduced proliferation of transferred BDC2.5 T cells to en-
dogenous pancreatic antigen in the NOD as an established surrogate
measure of tolerance induction [49], we were able to show that MN
administration of WE14 did indeed show tolerogenic potential.
Whilst we found that both ID andMN delivery ofWE14 could reduce
proliferation of transferred BDC2.5 cells to native antigen, MN deliv-
ery required less peptide to achieve the effect, in line with reports
that MNs provide a dose sparing effect for vaccination applications
[50].
Others have hypothesised that high afﬁnity mimotopes are better
than native peptides at inducing tolerance as they are more efﬁcient
at converting naïve T cells into Tregs [51]. However, our studies suggest
the opposite to be the case, with the native low-afﬁnity WE14 peptide
andnot thehigh-afﬁnitymimotope able to reduceproliferation of trans-
ferred cells. This is also in line with the ﬁnding that tolerising peptides
should ideally be both highly soluble and contain a native peptide
sequence [52].GC cream topical pre-treatment increased clearance of peptide from
the skin following ID injection. This appeared to be via increasing the
hydration of the treated skin tissue as a placebo vehicle cream had sim-
ilar effects (Supplementary Fig. 1). MN administration abrogated the
negative impact of GC or vehicle creampre-treatment on peptide reten-
tion compared to ID injection. As previously discussed,we believe that it
is undesirable for peptide to be rapidly lost from the skin in ASI [38,41]
and therefore MNs are likely to be better suited than ID injection for
peptide administration in conjunction with other topical pre-
treatments that may hydrate the underlying skin tissue.
Others have shown that systemic GC can enhance tolerance [24],
however it can also cause systemic immunosuppression [3]. We there-
fore used topical GC pre-treatment in an effort to enhance tolerance in-
ductionwhilstminimising systemic exposure and side effects. However,
in the protocol used, topical GC inhibited rather than augmented toler-
ance induction. We hypothesise that in our murine system local cell
death caused by topical steroid [53] is exacerbated by the thinner mu-
rine epidermis and results in a less tolerogenic environment in the
skin draining LN. This effect may be reduced in human skin (which is
substantially thicker [6], Supplementary Fig. 2) and we have recently
demonstrated that topical GC in humans promotes a tolerogenic pheno-
type in epidermal DCs [6]. In addition, alternative topical treatments
such as 1,25 dihydroxy-Vitamin D3 may have a net enhancing effect in
tolerance protocols when applied to human skin [49].
Previous studies have shown that epicutaneous antigen adminis-
tration can be tolerogenic in the context of allergies [54,55] and
autoimmune disease [56,57]. These reported epicutaneous toler-
ance protocols have exploited skin barrier disruption technologies
including transdermal patches, laser poration and tape stripping.
Clinical studies have shown that both food allergens, e.g. cow's
milk and peanut [58,59], and environmental allergens, such as pol-
len [59,60], delivered epicutaneously, i.e. superﬁcially into the skin,
can induce a protective response, although epicutaneous delivery
of exogenous antigen has also shown to reverse the tolerance in-
duced by oral delivery [61]. Both allergies and autoimmune diseases
can be classiﬁed as hyper-immune response conditions, therefore
tolerance protocols from allergy treatments have been adopted
and adapted for autoimmune disease. There are, however, funda-
mental differences between these two immune dysfunctions. Aller-
gies are triggered by transient exposure to one or more exogenous
antigens whilst autoimmunity results from constant exposure to
one or more endogenous antigens. Allergy is a Th2mediated immune
response whilst T1D is a Th1mediated immune response. The causal
factors are well characterised and identiﬁable with allergies and al-
lergen testing and therapies tend to be more effective. In the case of
autoimmune disease, there are usually a number of different anti-
gens involved and identiﬁcation of a single causal antigen is more
difﬁcult. Therefore, overall, the majority of the more clinically ad-
vanced tolerance protocols using epicutaneous administration are
targeted at reducing allergic (Th2-driven) responses, rather than
tolerising to prevent autoimmunity (primarily Th1 driven). It should
also be noted that the autoimmune disease, Experimental Autoim-
mune Encephalomyelitis (EAE), reported in the cited studies using
epicutaneous antigen administration [56,57] is an induced autoimmune
disease, produced with deﬁned antigens or peptides. The autoimmune
diabetes that we study, by contrast, occurs spontaneously in our
model and therefore, the application of epicutaneous therapy, consis-
tency and timing is much more problematical. We have previously
studied epicutaneous administration of antigen and this failed to induce
tolerance in diabetes (data not shown).
MNs have been widely used in the context of vaccine delivery [13–
16] and the induction of a pro-inﬂammatory response. More recently
they have also been reported to be able to increase Th1 response against
ovalbumin as a model allergen [21]. Our study demonstrates, for the
ﬁrst time, thatMNs have potential utility for thedelivery of endogenous,
low afﬁnity auto-antigens into human andmouse skin for the induction
186 X. Zhao et al. / Journal of Controlled Release 223 (2016) 178–187of tolerance in an autoimmune condition, T1D. Importantly, delivery of
the auto-antigen using coatedMNswasmore effective than ID injection
as a result of improved targeting to the superﬁcial skin layers, increased
residence time in the skin and more efﬁcient and persistent trafﬁcking
of the peptide to the lymph nodes. Auto-immune therapy is likely
to require chronic administration of the auto-antigen and therefore
the reduced pain associated with MNs and their potential for self-
administration will also offer signiﬁcant practical beneﬁts to those
at-risk individuals who may require preventative therapy for the
duration of their life.
Themethod of delivery ofWE14 using peptide-coatedMNs is poten-
tially translatable to humans asWE14 has recently been identiﬁed as an
antigen in human type 1 diabetes [62]. The technique also has the po-
tential to work with other known peptide auto-antigens such as insulin
B9-23 [63–65] and proinsulin C19-A3 [1,66], whole small proteins such
as proinsulin, as well as in other autoimmune diseases in which antigen
speciﬁc therapy has been developed [67]. Taken together with the ease
of self-administration and reduced discomfort of solidMNs as compared
to conventional ID administration, this approach may be particularly
suited to use in children and in “prevention” protocols for use in individ-
uals identiﬁed as being at a high risk of developing autoimmune disease
[68,69].
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